InvestorNewsBreaks – TC BioPharm Holdings PLC (NASDAQ: TCBP) Advances Preclinical Studies for Bird Flu Treatment with TCB008
TC BioPharm (NASDAQ: TCBP), a clinical-stage biotech company, announced plans to initiate Proof of Concept preclinical studies for its lead therapy, TCB008, targeting H5N1 "bird flu." TCB008 is an allogeneic gamma delta T cell therapy designed to leverage the immune system against infections like H5N1, which recently caused the first reported U.S. fatality in Louisiana. TC BioPharm aims to collaborate with leading infectious disease centers…